Patient P-01659
Therapy response
Improving
Tolerance
Deteriorating
GI state
Unstable
Inflammatory state
Unstable
Nutritional resilience
Unstable
Discontinuation risk
82%
Trajectory
Baseline → today → 30-day prediction · hover a day for signals and eventssolid = observed · dashed = predicted
- Day 0 NBL-101 started — Baseline state S14
- Day 31 NP-02 recommended — Dietary Support Protocol NP-02
- Day 32 Patient accepted — Started NP-02 in the companion
- Day 42 No meaningful change — Dietary Support Protocol NP-02
- Day 47 Trajectory diverged from prediction — Observed response fell below the model's expected path.
- Day 58 GI-04 recommended — GI Support Protocol GI-04
- Day 59 Patient accepted — Started GI-04 in the companion
- Day 67 GI symptom burden −26% vs expected — GI Support Protocol GI-04
- Day 73 Tolerance state changed — Unstable → Improving
What changed?
Trajectory began diverging from predicted response on Day 47.
Primary contributors, last 14 days
- Toxicity+14
- Nutritional resilience-11
- GI instability+7
- Inflammatory activity+6
- Treatment adherence-4
What helped?
- Dietary Support Protocol NP-02Day 31Result: no meaningful change
- GI Support Protocol GI-04Day 58Result: symptom burden −26%
LIFE OS recommendation
Monitoring Escalation ME-01
90%
probability of meaningful tolerance improvement
- 284 similar trajectories
- 100% showed improvement
- median effect visible after 3 days
Biological layers
Which pathways look influenced, and by which layer of this person's biology.
Pathways under pressure
- Mucosal barrier integrity ↓90
- DNAFUT2 non-secretor lowers mucosal fucosylation
- MicrobiomeAkkermansia low → thinner mucus layer
- Daily logGI symptom score 60 and rising
- WearableSleep 5.3 h, below personal baseline
- Butyrate / short-chain fatty acid production ↓80
- MicrobiomeButyrate capacity 38/100
- MicrobiomeF. prausnitzii depleted
- Daily logFibre intake low in recent food logs
- Inflammatory signalling ↑65
- DNAIL6 -174 variant raises baseline inflammatory tone
- BloodInflammatory load index 61
- WearableHRV 17 ms, trending down
- Drug metabolism and exposure ↑60
- DNACYP2D6 poor metabolizer → higher exposure
- BloodToxicity index 52
- Autonomic recovery ↓20
- WearableShort sleep window
DNA
Fictional pharmacogenomic panel
- FUT2 rs601338 AA (non-secretor)Reduced mucosal fucosylation
- IL6 -174 G/CHigher inflammatory tone
- CYP2D6 Poor metabolizerHigher exposure at standard dose
Microbiome
Shannon diversity 2.1 · butyrate capacity 38/100
- Akkermansia muciniphilaLow
- Faecalibacterium prausnitziiLow
- Bacteroides fragilisNormal
- Bifidobacterium longumLow
- EnterobacteriaceaeHigh
Wearable, last 14 days
daily evolution fed into the runtime
- HRV
- 24 ms
- Sleep
- 5.6 h
- Steps
- 5,932
- Resting HR
- 68 bpm
Daily log: GI score 60, nutritional resilience 34, adherence 46.
What this patient sees in NostraAI
The content that steers the trajectory: what to eat, what to do, what to take.
What to eat
- Prepare a plain, low-fat pasta or rice meal and note how it feels afterwards
- Choose a freshly cooked, lean protein; avoid frying, rich sauces and leftovers for now
- Add one soluble-fibre source (oats, cooked carrots, banana) to breakfast
- Avoid known triggers for now: fried or oily food, dairy, alcohol
What to do
- Track each bowel movement today: time, stool form, urgency, overnight waking
- Keep the current walking rhythm
- Protect a 7.5-hour sleep window; screens off 30 minutes before
- Keep hydration steady: small amounts through the day rather than large volumes at once
What to take
- Take the scheduled dose as agreed with your care team
- Electrolyte solution, one sachet after any loose stool
- Fictional demo item: oral nutrition supplement with lunch
284 biologically similar trajectories
Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.
| Patient | Similarity | Baseline | Intervention | Outcome | Response today |
|---|---|---|---|---|---|
| P-01327 | 37% | S01 | GI-04 | improved | 56 |
| P-01688 | 36% | S01 | GI-04 | improved | 40 |
| P-01813 | 35% | S01 | NP-02 | no change | 40 |
| P-01310 | 32% | S01 | — | — | 57 |
| P-01877 | 28% | S01 | CR-01 | improved | 67 |
| P-01823 | 21% | S01 | — | — | 57 |
| P-01604 | 20% | S01 | — | — | 71 |
| P-01635 | 36% | S02 | GI-04 | improved | 49 |
| P-01452 | 33% | S02 | GI-04 | improved | 46 |
| P-01459 | 30% | S02 | — | — | 51 |
| P-01499 | 21% | S02 | — | — | 65 |
| P-01498 | 20% | S02 | — | — | 56 |